Pharmacological Practice of Parenteral Direct Thrombin Inhibitors Guidelines

Title: Pharmacological Practice of Parenteral Direct Thrombin Inhibitors Guidelines
Edition: Original
Classification: Rapid advice guideline
Field: Treatment
Countries and regions: China
Guidelines users: 医生、护士、药师
Evidence classification method: GRADE
Development unit: Clinical Pharmacy Branch of Chinese Medical Association;Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Registration time: 2024-07-05
Registration number: PREPARE-2024CN954
Purpose of the guideline: 1、Standardizing Clinical Medication: Provide unified medication standards to help clinicians correctly select and use parenteral direct thrombin inhibitors, improving treatment efficacy and safety. 2、Enhancing Medication Safety: Reduce medication errors through the establishment of guidelines, decrease drug-related adverse reactions and complications, and ensure patient medication safety. 3、Optimizing Treatment Regimens: Optimize treatment regimens for parenteral direct thrombin inhibitors based on the latest research and clinical evidence, improving patient treatment outcomes. 4、Providing Education and Training: Offer relevant training and educational resources for healthcare professionals to enhance their understanding and ability to use parenteral direct thrombin inhibitors. 5、Promoting Clinical Research: Clarify research directions and priorities through guideline development, driving clinical research and innovation in the field of parenteral direct thrombin inhibitors. 6、Unifying Treatment Standards: Establish consistent treatment standards across different medical institutions, reducing regional and institutional disparities in medication use, ensuring all patients receive consistent treatment.